Erratum to review article: Imaging in the Investigation of Paraneoplastic Syndromes, Clinical Radiology 2007, 62(11): 1021-1035 (DOI:10.1016/j.crad.2007.06.005);Imaging in the investigation of paraneoplastic syndromes

Clinical Radiology

Volumn 62, Issue 11, 2007, Pages 1021-1035

  Rutherford, G C ^a   Dineen, R A ^a   O'Connor, A ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; FLUORODEOXYGLUCOSE F 18; HEPARIN; HU ANTIBODY; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACANTHOSIS NIGRICANS; ANAMNESIS; ANTIBODY DETECTION; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER RADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG RESPONSE; EATON LAMBERT SYNDROME; ECHOGRAPHY; ENCEPHALOMYELITIS; ERYTHEMA CHRONICUM MIGRANS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYPERCALCEMIA; HYPERTROPHIC OSTEOARTHROPATHY; INAPPROPRIATE VASOPRESSIN SECRETION; INTERMETHOD COMPARISON; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MAMMOGRAPHY; MYASTHENIA GRAVIS; MYOCLONUS; NEUROBLASTOMA; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS; OSTEOMALACIA; OVARIECTOMY; OVARY ADENOCARCINOMA; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PEMPHIGUS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SENSORY NEUROPATHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TESTIS TUMOR; THORAX RADIOGRAPHY; THYMECTOMY; THYMOMA; VENOUS THROMBOEMBOLISM; WHOLE BODY SCINTISCANNING;

EID: 34848877485     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2007.11.004     Document Type: Erratum

References (107)

1. Vedeler C.A., Antoine J.C., Giometto B., et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13 (2006) 682-690
2. Recommendations for cross-sectional imaging in cancer management. Ref no. RCR (06)1 (2006), The Royal College of Radiologists, London
3. Graus F., Delattre J.Y., Antoine J.C., et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr 75 (2004) 1135-1140
4. Gultekin S.H., Rosenfeld M.R., Voltz R., et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 (2000) 1481-1494
5. Urbach H., Soeder B.M., Jeub M., et al. Bien CG Serial MRI of limbic encephalitis. Neuroradiology 48 (2006) 380-386
6. Pozo-Rosich P., Clover L., Saiz A., et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 54 (2003) 530-533
7. Linke R., Schroeder M., Helmberger T., et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63 (2004) 282-286
8. Younes-Mhenni S., Janier M.F., Cinotti L., et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127 (2004) 2331-2338
9. Shams'ili S., Grefkens J., de Leeuw B., et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126 (2003) 1409-1418
10. Rees J.H. Paraneoplastic cerebellar degeneration: new insights into imaging and immunology. J Neurol Neurosurg Psychiatr 77 (2006) 427
11. Bataller L., Graus F., Saiz A., et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124 (2001) 437-443
12. Hayward K., Jeremy R.J., Jenkins S., et al. Long-term neurobehavioural outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 139 (2001) 552-559
13. Luque F.A., Furneaux H.M., Ferziger R., et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29 (1991) 241-251
14. Araki K., Ueda Y., Hayafuji M., et al. Opsoclonus-myoclonus syndrome with abnormal magnetic resonance imaging and brainstem auditory evoked potentials. Jpn J Med 28 (1989) 753-756
15. Hattori T., Hirayama K., Imai T., et al. Pontine lesion in opsoclonus-myoclonus syndrome shown by MRI. J Neurol Neurosurg Psychiatr 51 (1988) 1572-1575
16. Swart J.F., de Kraker J., and van der Lely N. Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome. Eur J Pediatr 161 (2002) 255-258
17. Antoine J.-C., Mosnier J.-F., Absi L., et al. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 67 (1999) 7-14
18. Molinuevo J.L., Graus F., Serrano C., et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 44 (1998) 976-980
19. Penn A.S., and Rowland L.P. Myasthenia Gravis. In: Rowland L.P. (Ed). Merritt's neurology. 10th ed (2000), Williams and Wilkins, Lippincott 721-727
20. Hale D.A., Cohen A.J., Schaefer P., et al. Computerized tomography in the evaluation of myasthenia gravis. South Med J 83 (1990) 414-416
21. Skeie G.O., Aarli J.A., and Gilhus N.E. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand 113 (2006 May) 19
22. Ellis K., and Austin J.H. Jaretzki A 3rd. Radiologic detection of thymoma in patients with myasthenia gravis. AJR Am J Roentgenol 151 (1988) 873-881
23. Batra P., and Herrmann Jr. C. Mediastinal Imaging in myasthenia gravis: correlation of chest radiography, CT, MR and surgical findings. AJR Am J Roentgenol 148 (1987) 515-519
24. Drachman D.B. Myasthenia gravis. N Engl J Med 330 (1994) 1797-1810
25. Fraser R.S., Muller N.L., Colman N., et al. Diagnosis of diseases of the chest. 4th ed (1999), WB Saunders, Philidelphia
26. Penn A.S. Lambert-Eaton syndrome. In: Rowland L.P. (Ed). Merritt's neurology. 10th ed (2000), Williams and Wilkins, Lippincott 727-728
27. Nakao Y.K., Motomura M., Fukudome T., et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59 (2002) 1773-1775
28. O'Neill J.H., Murray N.M.F., and Newsom-Davis J. The Lambert-Eaton syndrome. A review of 50 cases. Brain 111 (1988) 577-596
29. Motomura M., Johnston I., Lang B., et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58 (1995) 85-87
30. Lennon V.A., Kryzer T.J., Griesmann G.E., et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332 (1995) 1467-1475
31. Mason W.P., Graus F., Lang B., et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120 (1997) 1279-1300
32. Wirtz P.W., Willcox N., van der Slik A.R., et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 159 (2005) 230-237
33. Chalk C.H., Murray N.M., Newsom-Davis J., et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40 (1990) 1552-1556
34. Hettiarachchi R.J.K., Lok J., Prins M.H., et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence,risk indicators and diagnosis. Cancer 83 (1998) 180-185
35. Nordstrom M., Lindblad B., Anderson H., et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 308 (1994) 891-894
36. Sorenson H.T., Mellemkjoer L., Flemming H.S., et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338 (1998) 1169-1173
37. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992) 1128-1133
38. Prins M.H., Hettiarachchi R.J., Lensing A.W., et al. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?. Thromb Haemost 78 (1997) 121-125
39. British Thoracic Society Standards of Care Committee Pulmonary Embolism. British Thoracic Society Guidelines for the management of suspected acute pulmonary embolism. Thorax 58 (2003) 470-483
40. Pinzon R., Drewinko B., Trujillo J.M., et al. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer. J Clin Oncol 4 (1986) 509-514
41. Evans T.R., Mansi J.L., and Bevan D.H. Trousseau's syndrome in association with ovarian carcinoma. Cancer 77 (1996) 2544-2549
42. Tasi S.H., Juan C.J., Dai M.S., et al. Trousseau's syndrome related to adenocarcinoma of the colon and cholangiocarcinoma. Eur J Neurol 11 (2004) 493-496
43. Sack Jr. G.H., Levin J., and Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 56 (1977) 1-37
44. Wahrenbrock M., Borsig L., Le D., et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112 (2003) 853-862
45. Bell W.R., Starksen N.F., Tong S., et al. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med 79 (1985) 423-430
46. Callander N., and Rapaport S.I. Trousseau's Syndrome. West J Med 158 (1993) 364-371
47. Batsis J.A., and Morgenthaler T.I. Trousseau syndrome and the unknown cancer: use of positron emission tomographic imaging in a patient with a paraneoplastic syndrome. Mayo Clin Proc 80 (2005) 537-540
48. Sallah S., Sigounas G., Vos P., et al. Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. Ann Oncol 11 (2000) 1571-1577
49. Genty I., Michel M., Hermine O., et al. Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases. Rev Med Interne 23 (2002) 901-909
50. Rubinstein I., Langevitz P., Hirsch R., et al. Autoimmune hemolytic anemia as the presenting manifestation of malignant thymoma. Acta Haematol 74 (1985) 40-42
51. Payne D., Muss H.B., Homesley H.D., et al. Autoimmune hemolytic anemia and ovarian dermoid cysts: case report and review of the literature. Cancer 48 (1981) 721-724
52. Giannadaki E., Potamianos S., Roussomoustakaki M., et al. Autoimmune hemolytic anemia and positive Coombs test associated with ulcerative colitis. Am J Gastroenterol 92 (1997) 1872-1874
53. Plikat K., Rogler G., and Scholmerich J. Coombs-positive autoimmune hemolytic anemia in Crohn's disease. Eur J Gastroenterol Hepatol 17 (2005) 661-666
54. Suteanu S., Rohan C., Gherasim E., et al. Hypertrophic osteoarthropathy secondary to bronchopulmonary cancer (our experience). Rom J Intern Med 30 (1992) 281-284
55. Morgan B., Coakley F., Finlay D.B., et al. Hypertrophic osteoarthropathy in staging skeletal scintigraphy for lung cancer. Clin Radiol 51 (1996) 694-697
56. Uchisako H., Kazuyoshi S., Tanaka N., et al. Bone scintigraphy in growth hormone-secreting pulmonary cancer and hypertrophic osteoarthropathy. J Nucl Med 36 (1995) 822-825
57. Mito K., Maruyama R., Uenishi Y., et al. Hypertrophic pulmonary osteoarthropathy associated with non small cell lung cancer demonstrated growth hormone-releasing hormone by immunohistochemical analysis. Intern Med 40 (2001) 532-535
58. Olan F., Portela M., Navarro C., et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 31 (2004) 614-616
59. Davies R.A., Darby M., and Richards M.A. Hypertrophic pulmonary osteoarthropathy in pulmonary metastatic disease. A case report and review of the literature. Clin Radiol 43 (1991) 268-271
60. Biswal B.M., Kareem A., and Ahmed N.M. Hypertrophic osteoarthropathy: an unusual manifestation in nasopharyngeal cancer. Australas Radiol 45 (2001) 71-73
61. Goldstraw P., and Walbaum P.R. Hypertrophic osteoarthropathy and its occurrence with pulmonary metastases from renal carcinoma. Thorax 31 (1976) 205-211
62. Staalman C.R., and Umans U. Hypertrophic osteoarthropathy in childhood malignancy. Med Pediatr Oncol 21 (1993) 676-679
63. Rosenthall L., and Kirsh J. Observations of radionuclide imaging in hypertrophic pulmonary osteoarthropathy. Radiology 120 (1976) 359-362
64. Kroon H.M., and Pauwels E.K. Bone scintigraphy for the detection and follow-up of hypertrophic osteoartropathy. Diagn Imaging 51 (1982) 47-55
65. Albrecht S., and Keller A. Postchemotherapeutic reversibility of hypertrophic osteoarthropathy in a patient with bronchogenic adenocarcinoma. Clin Nucl Med 28 (2003) 463-466
66. Airio A., Pukkala E., and Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22 (1995) 1300-1303
67. Stockton D., Doherty V.R., and Brewster D.H. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85 (2001) 41-45
68. Chow W.H., Gridley G., Mellemkjaer L., et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6 (1995) 9-13
69. Hill C.L., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357 (2001) 96-100
70. Sigurgeirsson B., Lindelof B., Edhag O., et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326 (1992) 363-367
71. Anhalt G.J., Kim S.C., Stanley J.R., et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323 (1990) 1729-1735
72. Mehregan D.R., Oursler J.R., Leiferman K.M., et al. Paraneoplastic pemphigus: a subset of patients with pemphigus and neoplasia. J Cutan Pathol 20 (1993) 203-210
73. Joly P., Richard C., Gilbert D., et al. Sensitivity and specificity of clinical, histologic and immunological features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 43 (2000) 619-626
74. Mimouni D., Anhalt G.J., Lazarova Z., et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 147 (2002) 725-732
75. Kaplan I., Hodak E., Ackerman L., et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 40 (2004) 553-562
76. Kahn C.R., Flier J.S., Bar R.S., et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 294 (1976) 739-745
77. Rigel D.S., and Jacobs M.I. Malignant acanthosis nigricans: a review. J Dermatol Surg Onocl 6 (1980) 923-927
78. Kebria M.M., Belinson J., Kim R., et al. Malignant acanthosis nigricans, tripe palms and the sign of Lesr-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol 101 (2006) 353-355
79. Janier M., Blanchet-Bardon C., Bonvalet D., et al. Malignant acanthosis nigricans associated with non-Hodgkin's lymphoma. Report of 2 cases. Dermatologica 176 (1988) 133-137
80. List A.F., Hainsworth J.D., Davis B.W., et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 4 (1986) 1191-1198
81. Campling B.G., Sarda I.R., Baer K.A., et al. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 75 (1995) 2442-2451
82. Sorenson J.B., Andersen M.K., and Hansen H.H. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238 (1995) 97-110
83. Tho L.M., and Ferry D.R. Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety?. Postgrad Med J 81 (2005) 17
84. Gkonos P.J., Hayes T., Burtis W., et al. Squamous carcinoma model of humoral hypercalcaemia of malignancy. Endocrinology 115 (1984) 2384-2390
85. Stewart A.F., Romero R., Schwartz P.E., et al. Hypercalcaemia associated with gynaecological malignancies: biochemical characterization. Cancer 49 (1982) 2389-2394
86. Grill V., Ho P., Body J.J., et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73 (1991) 1309-1315
87. Jacobson J.O., Bringhurst F.R., Harris N.L., et al. Humoral hypercalcaemia in Hodgkin's disease. Clinical and laboratory evaluation. Cancer 63 (1989) 917-923
88. Mundy G.R. Pathogenesis of hypercalcaemia of malignancy. Clin Endocrinol 23 (1985) 705-714
89. Onuma E., Azuma Y., Saito H., et al. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcaemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin Cancer Res 11 (2005) 4198-4203
90. Syed M.A., Horwitz M.J., Tedesco M.B., et al. Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 86 (2001) 1525-1531
91. Yoshimoto K., Yamasaki R., Sakai H., et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcaemia. J Clin Endocrinol Metab 68 (1989) 976-981
92. Nielsen P.K., Rasmussen A.K., Feldt-Rasmussen U., et al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 81 (1996) 3793-3796
93. Mercier R.J., Thompson J.M., Harman G.S., et al. Recurrent hypercalcaemia and elevated 1,25-dihydroxy vitamin D levels in Hodgkin's disease. Am J Med 84 (1988) 165-168
94. Jonsson K.B., Zahradnik R., Larsson T., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348 (2003) 1656-1663
95. Clunie G.P., Fox P.E., and Stamp T.C. Four cases of acquired hypophosphataemic ("oncogenic") osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology 39 (2000) 1415-1421
96. Garcia C.A., and Spencer R.P. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med 27 (2002) 582-583
97. Roarke M.C., and Nguyen B.D. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 32 (2007) 300-301
98. Gonzalez-Compta X., Manos-Pujol M., Foglia-Fernandez M., et al. Oncogenic osteomalacia: case report and review of head and neck associated tumours. J Laryngol Otol 112 (1998) 389-392
99. Shim S.S., Lee K.S., Byung-Tae K., et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236 (2005) 1011
100. Ogunbiyi O.A., Flanagan F.L., Dehdashti F., et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 4 (1997) 613-620
101. Hoh C.K., Glaspy J., Rosen P., et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 38 3 (1997) 343-348
102. Rees J.H., Hain S.F., Johnson M.R., et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 124 (2001) 2223-2231
103. Hesse E., Moessinger E., and Rosenthal H. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 22 (2007) 158-162
104. Banayan S., Hot A., Janier M., et al. Malignant mesothelioma of the peritoneum as the cause of a paraneoplastic syndrome: detection by 18F-FDG PET. Eur J Nucl Med Mol Imaging 33 (2006) 751
105. Krug B., Sonet A., Pirson A.S., et al. FDG PET utility in paraneoplastic sweet syndrome. Clin Nucl Med 29 (2004) 91-92
106. 18F) FDG-PET. Q J Nucl Med 47 2 (2003) 85-89
107. Kumar J., Spring M., Carroll P.V., et al. 18Fluorodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol 64 (2006) 371-374